Physician profile
Michael Ignell
NPI 1568020006
$980.09
in general payments reported to CMS, 2019-2025
17 companies · $553 in 2025
The $553 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.88 · 2023: $82.20 · 2024: $318 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $953.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $128.47 | 2023-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $122.63 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $79.27 | 2024-2025 | |
| Boston Scientific Corporation | $76.33 | 2025 | Watchman Access System, General - Pain Management |
| Glaxosmithkline, LLC. | $73.35 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $65.92 | 2024-2025 | |
| Lilly USA, LLC | $61.21 | 2024-2025 | Zepbound, Kisunla, Mounjaro |
| Exact Sciences Corporation | $60.43 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $54.15 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $52.82 | 2024-2025 | Airsupra, Farxiga |
| Dynavax Technologies Corporation | $50.68 | 2024-2025 | Heplisav-B |
| Merck Sharp & Dohme LLC | $39.83 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Alnylam Pharmaceuticals INC. | $37.22 | 2024-2025 | Givlaari |
| Csl Behring | $26.88 | 2019 | |
| Astellas Pharma US INC | $18.88 | 2025 | Veozah |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $17.85 | 2025 | Loreev Xr |
| Phathom Pharmaceuticals, INC. | $14.17 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ignell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.